Pipeline
Advancing a Pipeline of First-in-Class Cancer Therapies
By combining our unrivaled Dark Antigen® discovery engine with our optimized T-cell engager platform, we are building a pipeline of differentiated cancer immunotherapies.
Our goal is to dramatically improve treatment outcomes for patients with solid tumors who remain underserved by today’s cancer immunotherapies.
ENA101 is a first-in-class bispecific TCE targeting a previously undiscovered Dark Antigen® that we have called DARKFOX™
DARKFOX™ is a compelling target for cancer immunotherapy:
- High prevalence across multiple solid tumors: including NSCLC, upper GI cancers, colorectal, breast, ovarian, head & neck, bladder, and multiple other cancers
- Deeply rooted in cancer biology: strong link to a gene that is critical in cancer initiation and progression, including the promotion and maintenance of cancer stem cells
- Hallmarks of optimal cancer targets: including minimal expression in normal tissues, homogeneous expression within tumors, and robust presentation on the surface of tumor cells
We have a longstanding strategic collaboration with Boehringer Ingelheim leveraging our EDAPT® platform to discover and validate Dark Antigens®
Antigen licensing
We reached a major milestone in this partnership when Boehringer Ingelheim exercised an option to license multiple Dark Antigens®. Based on these antigens, Boehringer is developing novel off-the-shelf vaccines for the treatment of non-small cell lung cancer (NSCLC).
Discovering more targets
Boehringer Ingelheim also triggered an additional component of the collaboration to discover Dark Antigens® in another undisclosed solid tumor.
Learn about our innovative platforms
Discover how our science is driving the development of first-in-class immunotherapies designed to transform patient care.